Drugs in preclinical and early-stage clinical development for pancreatic cancer

Expert Opinion on Investigational Drugs

Volumn 21, Issue 2, 2012, Pages 143-152

  Asuthkar, Swapna ^a   Rao, Jasti S ^a   Gondi, Christopher S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Chemo sensitivity; Gemcitabine; Molecular targets; Pancreatic cancer

Indexed keywords

ADI PEG 20; ANTINEOPLASTIC AGENT; BOSUTINIB; CAPECITABINE; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYDROXYCHLOROQUINE; IRINOTECAN; OXALIPLATIN; TRIPHENDIOL; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANGIOGENESIS; CANCER GENE THERAPY; CANCER SURGERY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DIARRHEA; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATICODUODENECTOMY; RASH; REVIEW;

ANIMALS; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; HUMANS; PANCREATIC NEOPLASMS;

EID: 84855766345     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.651124     Document Type: Review

References (104)

1. Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev 2003;27:87-93 (Pubitemid 36429586)
2. Inoue M, Yamamoto S, Kurahashi N, et al. Daily total physical activity level and total cancer risk in men and women: results from a large-scale populationbased cohort study in Japan. Am J Epidemiol 2008;168:391-403
3. Mysliwiec P, Kedra B. Causes of delayed diagnosis of pancreatic cancer. Own study and proposed algorithm. Przegl Lek 2008;65:345-8
4. Dhayat S, Mardin WA, Mees ST, Haier J. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer-a review. Int J Cancer 2011;129:1031-41
5. Tranah GJ, Holly EA, Wang F, Bracci PM. Cigarette, cigar and pipe smoking, passive smoke exposure, and risk of pancreatic cancer: a population-based study in the San Francisco Bay Area. BMC Cancer 2011;11:138
6. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997;89:442-6 (Pubitemid 27136736)
7. Danes BS, Lynch HT. A familial aggregation of pancreatic cancer. An in vitro study. JAMA 1982;247:2798-802 (Pubitemid 12105014)
8. Lynch HT, Fitzsimmons ML, Smyrk TC, et al. Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am J Gastroenterol 1990;85:54-60 (Pubitemid 20038980)
9. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91 (Pubitemid 39025053)
10. Cowgill SM, Muscarella P. The genetics of pancreatic cancer. Am J Surg 2003;186:279-86 (Pubitemid 38372178)
11. Lochan R, Daly AK, Reeves HL, Charnley RM. Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma. J Oncol 2011;2011:215985
12. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 2009;133:365-74
13. Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010;139:1076-80.1080
14. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009;302:1790-5
15. Kluijt I, Cats A, Fockens P, et al. Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance. J Clin Gastroenterol 2009;43:853-7
16. Naderi A, Couch FJ. BRCA2 and pancreatic cancer. Int J Gastrointest Cancer 2002;31:99-106 (Pubitemid 36330111)
17. Tokura M, Kamisawa T, Kuwata G, et al. Pancreatic cancer as the fourth cancer in a patient with Peutz-Jeghers syndrome and a history of familial pancreatic cancer. Pancreas 2011;40:169-70
18. Abou-Alfa GK, Chapman PB, Feilchenfeldt J, et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 2011;34:321-5
19. Brody JR, Costantino CL, Potoczek M, et al. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol 2009;22:651-9
20. Li J, Weghorst CM, Tsutsumi M, et al. Frequent p16INK4A/CDKN2A alterations in chemically induced Syrian golden hamster pancreatic tumors. Carcinogenesis 2004;25:263-8 (Pubitemid 38258166)
21. Grant WB, Mohr SB. Ecological studies of ultraviolet B, vitamin D and cancer since 2000. Ann Epidemiol 2009;19:446-54
22. Kinoshita S, Wagatsuma Y, Okada M. Geographical distribution for malignant neoplasm of the pancreas in relation to selected climatic factors in Japan. Int J Health Geogr 2007;6:34
23. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009;6:699-708
24. Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet 1997;349:485-9 (Pubitemid 27077838)
25. Long J, Zhang Y, Yu X, et al. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 2011;15:817-28
26. Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 2005;128:1642-54 (Pubitemid 40692557)
27. Meriggi F, Forni E. Extended lymphadenectomy for carcinoma of pancreatic head. Personal experience. G Chir 2002;23:383-90
28. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621-33
29. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903 (Pubitemid 15040883)
30. Neoptolemos JP, Raraty MG, Ghaneh P, et al. Adjuvant and additive therapy for cancer of the pancreas. Chirurg 2003;74:191-201 (Pubitemid 38264808)
31. Neoptolemos JP, Stocken DD, Dunn JA, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758-68 (Pubitemid 33117196)
32. Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005;92:1372-81 (Pubitemid 40705002)
33. Boeck S, Ankerst DP, Heinemann V. The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis. Oncology 2007;72:314-21 (Pubitemid 351238143)
34. Drudi F, Tassinari DCC, Carloni FSC, et al. Adjuvant treatments in pancreatic cancer: Preliminary data of a pooled analysis. J Clin Oncol 2011; 29(Suppl):abstract #4042
35. Khanna A, Walker GR, Livingstone AS, et al. Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg 2006;10:689-97 (Pubitemid 43732383)
36. Neoptolemos JP, Stocken DD, Tudur SC, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3(v1) trials. Br J Cancer 2009;100:246-50
37. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267-77 (Pubitemid 46143304)
38. Richter J, Saif MW. Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium"; 22-24 January 2010; Orlando, FL, USA. JOP 2010;11:144-7
39. Sawaki A, Hoki N, Ito S, et al. Clinical impact of radiotherapy for locally advanced pancreatic cancer. J Gastroenterol 2009;44:1209-14
40. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6 (Pubitemid 46972777)
41. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81
42. Hirao K, Kawamoto H, Sakakihara I, et al. A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity. Int J Clin Oncol 2011;16(6):637-45
43. Gong JF, Zhang XD, Li J, et al. Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer. Ai Zheng 2007;26:890-4
44. Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-Fluorouracil/ Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma. Oncology 2011;80:301-6
45. Lowery MA, O'Reilly EM. New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy. BioDrugs 2011;25:207-16
46. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
47. Oberstein PE, Saif MW. First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium"; 20-22 January 2011; San Francisco, CA, USA. JOP 2011;12:96-100
48. Chan E, Mulkerin D, Rothenberg M, et al. A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Invest New Drugs 2008;26:241-7
49. Patterson AV, Ferry DM, Edmunds SJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 2007;13:3922-32 (Pubitemid 47037600)
50. Mornex F, Girard N, Scoazec JY, et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: the French SFRO-FFCD 97-04 Phase II trial. Int J Radiat Oncol Biol Phys 2006;65:1471-8 (Pubitemid 44164277)
51. Bhutia YD, Hung SW, Patel B, et al. CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res 2011;71:1825-35
52. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002;2:133-42
53. DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 2005;15:356-63 (Pubitemid 40943524)
54. Koide N, Yamada T, Shibata R, et al. Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clin Cancer Res 2006;12:2419-26
55. Groysman M, Hornstein I, Alcover A, Katzav S. Vav1 and Ly-GDI two regulators of Rho GTPases, function cooperatively as signal transducers in T cell antigen receptor-induced pathways. J Biol Chem 2002;277:50121-30 (Pubitemid 36014465)
56. Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, et al. Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell 2005;7:39-49 (Pubitemid 40126381)
57. Miyashita K, Nakada M, Shakoori A, et al. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta. Anticancer Agents Med Chem 2009;9:1114-22
58. Hilbig A. Src kinase and pancreatic cancer. Recent Results Cancer Res 2008;177:179-85
59. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 2000;60:1091-9
60. Park SI, Shah AN, Zhang J, Gallick GE. Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors. Expert Opin Ther Targets 2007;11:1207-17 (Pubitemid 47527325)
61. Messersmith WA, Rajeshkumar NV, Tan AC, et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther 2009;8:1484-93
62. Duxbury MS, Ito H, Benoit E, et al. CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness. Br J Cancer 2004;91:1384-90 (Pubitemid 39424802)
63. Strickland LA, Ross J, Williams S, et al. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol 2009;218:380-90
64. Duxbury MS, Ito H, Ashley SW, Whang EE. c-Src-dependent cross-talk between CEACAM6 and alphavbeta3 integrin enhances pancreatic adenocarcinoma cell adhesion to extracellular matrix components. Biochem Biophys Res Commun 2004;317:133-41 (Pubitemid 38401974)
65. Duxbury MS, Ito H, Benoit E, et al. Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. Oncogene 2004;23:5834-42 (Pubitemid 39093029)
66. Duxbury MS, Ito H, Benoit E, et al. A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res 2004;64:3987-93 (Pubitemid 38697314)
67. Duxbury MS, Ito H, Zinner MJ, et al. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 2004;23:465-73 (Pubitemid 38175001)
68. Duxbury MS, Ito H, Ashley SW, Whang EE. CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma. Biochem Biophys Res Commun 2004;317:837-43 (Pubitemid 38481448)
69. Kashiwaya K, Hosokawa M, Eguchi H, et al. Identification of C2orf18, termed ANT2BP (ANT2-binding protein), as one of the key molecules involved in pancreatic carcinogenesis. Cancer Sci 2009;100:457-64
70. Gorantla B, Asuthkar S, Rao JS, et al. Suppression of the uPAR-uPA system retards angiogenesis, invasion, and in vivo tumor development in pancreatic cancer cells. Mol Cancer Res 2011;9:377-89
71. He Y, Liu XD, Chen ZY, et al. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin Cancer Res 2007;13:3115-24 (Pubitemid 46944892)
72. Bauer TW, Liu W, Fan F, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met-and insulin-like growth factor-I receptormediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005;65:7775-81 (Pubitemid 41297252)
73. Hildenbrand R, Niedergethmann M, Marx A, et al. Amplification of the urokinase-type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am J Pathol 2009;174:2246-53
74. Xue A, Scarlett CJ, Jackson CJ, et al. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas 2008;36:160-7
75. Chandrasekar N, Mohanam S, Gujrati M, et al. Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells. Oncogene 2003;22:392-400 (Pubitemid 36194335)
76. Huang GJ, Yang CM, Chang YS, et al. Hispolon suppresses SK-Hep1 human hepatoma cell metastasis by inhibiting matrix metalloproteinase-2/9 and urokinase-plasminogen activator through the PI3K/Akt and ERK signaling pathways. J Agric Food Chem 2010;58:9468-75
77. Huang HY, Jiang ZF, Li QX, et al. Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator. Cancer Invest 2010;28:689-97
78. Lai KC, Huang AC, Hsu SC, et al. Benzyl isothiocyanate (BITC) inhibits migration and invasion of human colon cancer HT29 cells by inhibiting matrix metalloproteinase-2/-9 and urokinase plasminogen (uPA) through PKC and MAPK signaling pathway. J Agric Food Chem 2010;58:2935-42
79. Uchima Y, Sawada T, Hirakawa K. Action of antiproteases on pancreatic cancer cells. JOP 2007;8:479-87 (Pubitemid 47263689)
80. Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006;124:1111-15
81. Subramaniam D, Ramalingam S, Houchen CW, Anant S. Cancer stem cells: a novel paradigm for cancer prevention and treatment. Mini Rev Med Chem 2010;10:359-71
82. Katari UL, Keirnan JM, Worth AC, et al. Engineered T cells for pancreatic cancer treatment. HPB (Oxford) 2011;13:643-50
83. Shankar S, Nall D, Tang SN, et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 2011;6:e16530
84. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol 2008;26:2806-12
85. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007;26:1357-60 (Pubitemid 46328461)
86. Morton JP, Mongeau ME, Klimstra DS, et al. Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proc Natl Acad Sci USA 2007;104:5103-8 (Pubitemid 47186183)
87. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-6 (Pubitemid 37355945)
88. Chun SG, Zhou W, Yee NS. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. Cancer Biol Ther 2009;8:1328-39
89. Tiede S, Paus R. Lhx2-decisive role in epithelial stem cell maintenance, or just the "tip of the iceberg"? Bioessays 2006;28:1157-60 (Pubitemid 44925434)
90. Gutova M, Najbauer J, Frank RT, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 2008;26:1406-13
91. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009;136:642-55
92. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007;297:1901-8 (Pubitemid 46707844)
93. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27:5848-56
94. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007;120:1046-54 (Pubitemid 46214304)
95. Szafranska AE, Doleshal M, Edmunds HS, et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 2008;54:1716-24
96. Asangani IA, Rasheed SA, Nikolova DA, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008;27:2128-36 (Pubitemid 351485639)
97. Gabriely G, Wurdinger T, Kesari S, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2008;28:5369-80
98. Moriyama T, Ohuchida K, Mizumoto K, et al. MicrRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 2009;8:1067-74
99. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006;24:4677-84 (Pubitemid 46630931)
100. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130:2113-29 (Pubitemid 43816961)
101. Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or-221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009;38:e190-9
102. Jung DE, Wen J, Oh T, Song SY. Differentially expressed MicroRNAs in pancreatic cancer stem cells. Pancreas 2011; Epub ahead of print
103. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med 2009;13:39-53
104. Preis M, Gardner TB, Gordon SR, et al. MicroRNA-10b Expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res 2011;17:5812-21